

RECEIVED
CENTRAL FAX CENTER

JUL 17 2006

PATENT

DOCKET NO.: ISIS-5207
Application No.: 10/701,236
Restriction Requirement Mailed: June 21, 2006

REMARKS

The Restriction Requirement mailed June 21, 2006 in connection with the above-identified patent application the Office has restricted claims 1-67 into one group and further restricted these claims into inventions a through p. Applicants elect Group I and further elect invention l (claims 12 and 37) with traverse with respect to invention m (claims 12 and 37). The 4'-thioribonucleoside and the 2'-deoxy-4'-thioribonucleoside, of inventions l and m respectively, are substantially structurally similar differing only in that the 4'-thioribonucleoside has a 2'-OH and the 2'-deoxy-4'-thioribonucleoside has a 2'-H. This minor structural difference should pose no burden for searching purposes. The election of group I, inventions l and m, read on claims 1-10, 12, 25, 28-35, 37, 50 and 53-67.

A listing of the claims have been included to clarify the election and to correct for minor typographical errors. Claims 1, 28, 33 and 53 have been amended, claims 2-10, 29-32, 34-35 and 54-67 are as originally filed and claims 11-27 and 36-52 are withdrawn. Claims 1, 28 and 53 have been amended to incorporate the limitation of a respective dependent claim to limit the sugar surrogate group to 4'-thioribonucleoside or 2'-deoxy-4'-thioribonucleoside. Claim 33 has been amended for a typographical error. No new matter has been added.

DOCKET NO.: ISIS-5207
Application No.: 10/701,236
Restriction Requirement Mailed: June 21, 2006

PATENT

Conclusion

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121.

Respectfully submitted,

Robert S. Andrews

Date: June 17, 2006

Robert S. Andrews

Registration No. 44,508

Isis Pharmaceuticals, Inc.

1896 Rutherford Road

Carlsbad, CA 92008

Telephone: (760) 603-2352

Facsimile: (760) 603-3820